Raised $150M across disclosed rounds.[2][3][4][9]

Series B closed November 2025, led by Bezos Expeditions.[1][2][3][4][5][9]

post-money valuation is not publicly disclosed.

Named investors include Insight Partners, Air Street Capital, AIX Ventures, Phoenix Venture Partners, Spark Capital, Bezos Expeditions, Altimeter Capital.[7][8][1][2][3][4][5][9]

Ali Madani, Founder and CEO[10][11][16]

Alexander Meeske, Co-Founder[10][11][16]

Hilary Eaton, Chief Business Officer[12][13][14][15][16]

Peter Cameron, SVP, Gene Editing and Translation[12][13][14][15][16]

Aaron Schwartz, General Manager, Emerging Technology[12][13][14][15][16]

Stephen Nayfach, Head of Bioinformatics and Platform R&D[12][13][14][15][16]

Isomorphic Labs · isomorphiclabs.com · Competes for AI biotech talent, pharma partnerships, and the thesis that AI models can design therapeutics; Isomorphic raised $600M in 2025.[1]

InSilico Medicine · insilico.com · Overlaps on AI-driven therapeutic design and pharma partnerships; raised $123M in 2025.[1]

Ginkgo Bioworks · ginkgobioworks.com · Overlaps on protein engineering services and agriculture partnerships; Profluent hired Ginkgo's former VP of BD.[14]

Filled in the side panel for invited readers. This card carries sourced facts only.